TY - JOUR
T1 - New anticoagulants for the prevention and treatment of venous thromboembolism
AU - Kim, Joo Hee
AU - Lim, Kyung Min
AU - Gwak, Hye Sun
N1 - Funding Information:
This work is supported by the National Research Foundation of Korea (Grant No. NRF-2015R1D1A1A01057931).
Publisher Copyright:
© 2017 The Korean Society of Applied Pharmacology.
PY - 2017/9
Y1 - 2017/9
N2 - Anticoagulant drugs, like vitamin K antagonists and heparin, have been the mainstay for the treatment and prevention of venous thromboembolic disease for many years. Although effective if appropriately used, traditional anticoagulants have several limitations such as unpredictable pharmacologic and pharmacokinetic responses and various adverse effects including serious bleeding complications. New oral anticoagulants have recently emerged as an alternative because of their rapid onset/offset of action, predictable linear dose-response relationships and fewer drug interactions. However, they are still associated with problems such as bleeding, lack of reversal agents and standard laboratory monitoring. In an attempt to overcome these drawbacks, key steps of the hemostatic pathway are investigated as targets for anticoagulation. Here we reviewed the traditional and new anticoagulants with respect to their targets in the coagulation cascade, along with their therapeutic advantages and disadvantages. In addition, investigational anticoagulant drugs currently in the development stages were introduced.
AB - Anticoagulant drugs, like vitamin K antagonists and heparin, have been the mainstay for the treatment and prevention of venous thromboembolic disease for many years. Although effective if appropriately used, traditional anticoagulants have several limitations such as unpredictable pharmacologic and pharmacokinetic responses and various adverse effects including serious bleeding complications. New oral anticoagulants have recently emerged as an alternative because of their rapid onset/offset of action, predictable linear dose-response relationships and fewer drug interactions. However, they are still associated with problems such as bleeding, lack of reversal agents and standard laboratory monitoring. In an attempt to overcome these drawbacks, key steps of the hemostatic pathway are investigated as targets for anticoagulation. Here we reviewed the traditional and new anticoagulants with respect to their targets in the coagulation cascade, along with their therapeutic advantages and disadvantages. In addition, investigational anticoagulant drugs currently in the development stages were introduced.
KW - Anticoagulant
KW - Heparin
KW - Venous thromboembolism
KW - Vitamin K antagonist
UR - http://www.scopus.com/inward/record.url?scp=85029153282&partnerID=8YFLogxK
U2 - 10.4062/biomolther.2016.271
DO - 10.4062/biomolther.2016.271
M3 - Review article
AN - SCOPUS:85029153282
SN - 1976-9148
VL - 25
SP - 461
EP - 470
JO - Biomolecules and Therapeutics
JF - Biomolecules and Therapeutics
IS - 5
ER -